Topics

PubMed Journals Articles About "More Veggies Help During Prostate Cancer Surveillance" RSS

12:49 EDT 3rd April 2020 | BioPortfolio

More Veggies Help During Prostate Cancer Surveillance PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest More Veggies Help During Prostate Cancer Surveillance articles that have been published worldwide.

More Information about "More Veggies Help During Prostate Cancer Surveillance" on BioPortfolio

We have published hundreds of More Veggies Help During Prostate Cancer Surveillance news stories on BioPortfolio along with dozens of More Veggies Help During Prostate Cancer Surveillance Clinical Trials and PubMed Articles about More Veggies Help During Prostate Cancer Surveillance for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of More Veggies Help During Prostate Cancer Surveillance Companies in our database. You can also find out about relevant More Veggies Help During Prostate Cancer Surveillance Drugs and Medications on this site too.

Showing "More Veggies Help During Prostate Cancer Surveillance" PubMed Articles 1–25 of 18,000+

Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?

To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with low-risk prostate cancer (PCa) at one-year in active surveillance (AS).


Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Active surveillance (AS) is an accepted means of managing low-risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis and mortality. This study projected the comparative benefits of different AS schedules in men diagnosed with prostate cancer who had Gleason score (GS) ≤6 disease and risk profiles similar to those in North American AS cohorts.

Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.

Men with germline mutations in DNA-repair genes have a higher risk of developing prostate cancer. Active surveillance (AS) is the preferred treatment modality for low-risk prostate cancer. However, many fear to offer this alternative to men with germline mutations. We now describe the short-term oncologic outcomes of active surveillance in a population of men with a high genetic predisposition for developing prostate cancer.


Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.

Transrectal, ultrasonography-guided prostate biopsy often fails to disclose the severity of underlying pathologic findings for prostate cancer. Magnetic resonance imaging (MRI)-guided biopsy may improve the characterization of prostate pathologic results, but few studies have examined its use for the decision to enter active surveillance.

Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study.

Active surveillance (AS) is an increasingly utilized strategy for monitoring men with low-risk prostate cancer (PCa) that allows them to defer active treatment (AT) in the absence of cancer progression. Studies have explored reasons for selecting AS and for then switching to AT, but less is known about men's experiences being on AS. We interviewed men to determine the clinical and psychological factors associated with selecting and adhering to AS protocols.

Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.

To study the risk of metastatic prostate cancer development in men with Grade Group 2 disease being managed with active surveillance (AS) at Memorial Sloan Kettering Cancer Center.

Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).

This study compares the side effects of active surveillance, prostatectomy, radiation with or without adjuvant endocrine therapy, watchful waiting, and palliative therapy on patient-reported outcomes in a nationwide, population-based cohort of Danish men with prostate cancer.

Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study.

Knowledge about factors influencing choice of and adherence to active surveillance (AS) for prostate cancer (PC) is scarce. We aim to identify which factors most affected choosing and adhering to AS and to quantify their relative importance.

Evaluation of apparent diffusion coefficient as a predictor of grade reclassification in men on active surveillance for prostate cancer.

To evaluate the association between apparent diffusion coefficient (ADC) on initial multiparametric MRI (mpMRI) and biopsy grade reclassification (GR) to Grade Group (GG) ≥ 2 prostate cancer (PCa) in men on active surveillance (AS) with GG 1 PCa.

Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.

Active surveillance (AS) protocols rely on rectal examination, prostate-specific antigen, imaging, and biopsy to identify disease progression.

Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment.

This study aims to describe the pathological features and clinical outcomes in anterior-dominant prostate cancer (APCA) compared to posterior/posterolateral-dominant prostate cancer (PPCA) among men treated with radical prostatectomy for localized prostate cancer.

A CD24-p53 axis contributes to African American prostate cancer disparities.

Using a functional analysis of prostate cancer cells, we found a CD24-dependent inactivation of mutant p53, but the clinical significance of this observation remained uncertain. Here, we validated these results with samples of human prostate cancer and explored the role of a CD24-p53 axis in racial disparities of prostate cancer.

Associations between self-reported physical activity, quality of life and emotional well-being in men with prostate cancer on active surveillance.

The relationship between physical activity (PA) and quality of life (QOL) relative to active treatment for prostate cancer (PCa) has been well-studied; however, little is known about this relationship during active surveillance (AS). Moreover, whether PA is associated with better emotional well-being (EWB) in men with low-risk PCa requires further investigation. Accordingly, we examined the association between self-reported PA and the average change in QOL and EWB over time during AS.

Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance.

We aimed to investigate the correlation between presence of inflammation and pathology upgrading/upstaging in patients with prostate cancer.

The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review.

5-14% of patients underwent surgery for benign prostate hyperplasia harboring prostate cancer (PCa) focus. The best management of incidental prostate cancer (iPCa) has been debated. The decision "treatment or no treatment" should be determined by predictors which accurately foretell PCa progression after transurethral resection of the prostate (TURP). The purpose of this study is to review the available data that can be useful in daily clinical judgment. Transrectal ultrasound prostate biopsy (TRUSBx) did n...

The Role of PSA Monitoring after Holmium Laser Enucleation of the Prostate (HoLEP).

Prostate specific antigen (PSA) screening for prostate cancer has recently been challenged due to poor sensitivity. A number of conditions elevate PSA besides prostate cancer with benign prostatic hypertrophy (BPH) being most common. The objective of this study was to assess the positive predictive value (PPV) of PSA and PSA density (PSAD) for prostate cancer risk following Holmium laser enucleation of the prostate (HoLEP).

Neuroendocrine prostate cancer: long noncoding RNAs to treat an incurable cancer - an interview with Dr Francesco Crea.

Dr Crea's lab studies the role of epigenetic factors and noncoding RNA in cancer initiation and progression. While working at the National Cancer Institute (USA), Dr Crea has demonstrated that polycomb-targeting drugs eradicate prostate cancer stem cells. While working at the BC Cancer Agency (Canada), Dr Crea discovered and patented , a long noncoding RNA involved in prostate cancer metastasis. Dr Crea has received awards from the American Society of Clinical Oncology, from the Prostate Cancer Program a...

Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study.

To determine the accurate age-adjusted incidence of prostate small cell carcinoma (SCC), update the clinical and pathological characteristics, as well as survival data of prostate SCC from Surveillance, Epidemiology, and End Results (SEER) datasets.

Granulomatous Prostatitis Mimicking Prostate Cancer.

Multiparametric magnetic resonance imaging (mpMRI) plays an important role in the detection of clinically significant prostate cancer. However, there is some overlap between prostate cancer and granulomatous prostatitis. We describe the imaging features of granulomatous prostatitis, which frequently mimics prostate cancer, and differential diagnosis between these conditions according to Prostate Imaging-Reporting and Data System (PI-RADS) version 2.1.

Risk stratification and avoiding overtreatment in localized prostate cancer.

Significant morbidity is associated with overtreatment of clinically localized prostate cancer (PCa). Risk stratification tools such as novel biomarkers, MRI and risk calculators are useful in predicting which patients would benefit from active surveillance. This review examines current risk stratification tools in localized PCa and the safety of active surveillance in these patients.

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection.

Long Non-coding RNAs in Prostate Cancer: Functional Roles and Clinical Implications.

Long noncoding RNAs (lncRNAs) are defined as RNA transcripts longer than 200 nucleotides that do not encode proteins. LncRNAs have been documented to exhibit aberrant expression in various types of cancer, including prostate cancer. Currently, screening for prostate cancer results in overdiagnosis. The consequent overtreatment of patients with indolent disease in the clinic is due to the lack of appropriately sensitive and specific biomarkers. Thus, the identification of lncRNAs as novel biomarkers and ther...

Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study.

COMPARE (COMparing treatment options for ProstAte cancer) aimed to evaluate and quantify the trade-offs patients make between different aspects of active surveillance and definitive therapy.

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.

The use of 12-core systematic prostate biopsy is associated with diagnostic inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer. Biopsies performed with magnetic resonance imaging (MRI) targeting may reduce the misclassification of prostate cancer in men with MRI-visible lesions.

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.

Prostate cancer is ubiquitous in older men; differential screening patterns and variations in biopsy recommendations and acceptance will affect which man is diagnosed and, therefore, evaluation of cancer risk factors. We describe a statistical method to reduce prostate cancer detection bias among African American (n = 3398) and Non-Hispanic White men (n = 22,673) who participated in the Selenium and Vitamin E Cancer Prevention trial (SELECT) and revisit a previously reported association between race...


Quick Search